For the year ending 2025-12-31, XAGE made $1,912,811 in revenue. -$6,905,282 in net income. Net profit margin of -361.00%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Net sales | 1,912,811 | 50,318 | ||
| Cost of sales | 818,051 | 6,357 | ||
| Gross profit | 1,094,760 | 43,961 | ||
| Selling and marketing | 1,423,045 | 189,323 | ||
| Research and development | 788,888 | 1,054,310 | ||
| General and administrative | 5,911,725 | 3,715,340 | ||
| Depreciation and amortization of intangible assets | 78,675 | 83,486 | ||
| Total operating expenses | 8,202,333 | 5,042,459 | ||
| Loss from operations | -7,107,573 | -4,998,498 | ||
| Other income | 168,146 | 44,798 | ||
| Interest expense | 18,214 | 29,466 | ||
| Change in fair value of earnout liabilities | -149,584 | - | ||
| Loss on lease termination | - | -44,577 | ||
| Inventory write-down | 60,963 | - | ||
| Amortization of debt discount | 0 | 19,549 | ||
| Loss on forward purchase agreement | 0 | 5,700,451 | ||
| Loss on lease termination | 0 | - | ||
| Total other income (expense) | 238,553 | -5,749,245 | ||
| Loss from continuing operations before income taxes | -6,869,020 | -10,747,743 | ||
| Income tax expense (benefit) | 36,262 | -97,279 | ||
| Loss from continuing operations | -6,905,282 | -10,650,464 | ||
| Loss from discontinued operations, net of tax | 0 | -1,152,276 | ||
| Gain on sale of discontinued operations | 0 | 1,434,479 | ||
| Net loss | -6,905,282 | -10,368,261 | ||
| Net loss attributable to common stockholders | - | -10,368,261 | ||
| Basic EPS | -4.83 | -0.49 | ||
| Diluted EPS | -4.83 | -0.49 | ||
| Basic Average Shares | 1,429,557 | 21,362,735 | ||
| Diluted Average Shares | 1,429,557 | 21,362,735 | ||
Longevity Health Holdings, Inc. (XAGE)
Longevity Health Holdings, Inc. (XAGE)